Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals Q3 net loss widens to $73.6 million from $42.2 million

Negative Impact 3 of 5 earnings

Olema Pharmaceuticals reported a wider third-quarter 2026 net loss of $73.6 million, or $0.73 per share, versus $42.2 million, or $0.49 per share, a year earlier. The filing shows higher research and development and general and administrative spending tied to its Phase 3 trials and early preparations for a possible launch of palazestrant. Shareholders face a higher cash burn, with $413.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.

Key points

  • Net loss was $73.6 million for the quarter ended September 30, 2026, compared with $42.2 million a year earlier.
  • GAAP research and development expenses rose to $67.6 million from $40.0 million; G&A expenses rose to $9.9 million from $5.9 million.
  • Cash, cash equivalents, and marketable securities were $413.8 million at September 30, 2026.
  • The company expects top-line data from the Phase 3 OPERA-01 trial in the first quarter of 2027 and appointed Jason O'Byrne as Chief Financial Officer.

The filing

CompanyOlema Pharmaceuticals, Inc. (OLMA)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:05 AM ET
Accession number0001193125-26-454403

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:11 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.